Results 51 to 60 of about 37,664 (239)

Circular RNA circSMAD4 regulates cardiac fibrosis by targeting miR-671-5p and FGFR2 in cardiac fibroblasts

Molecular Therapy: Nucleic Acids, 2023
Heart failure is a leading cause of death and is often accompanied by activation of quiescent cardiac myofibroblasts, which results in cardiac fibrosis. In this study, we aimed to identify novel circular RNAs that regulate cardiac fibrosis.
A. Jeong, Y. Lim, T. Kook, D. Kwon, Young Kuk Cho, J. Ryu, Yun-Gyeong Lee, Sera Shin, N. Choe, Yong Sook Kim, Hye Jung Cho, Jeong Chul Kim, Yoonjoo Choi, Su-Jin Lee, Hyung-Seok Kim, H. Kee, K. Nam, Youngkeun Ahn, M. H. Jeong, W. Park, Young-Kook Kim, H. Kook   +21 more
semanticscholar   +1 more source

Activating somatic FGFR2 mutations in breast cancer. [PDF]

PLoS ONE, 2013
It is known that FGFR2 gene variations confer a risk for breast cancer. FGFR2 and FGF10, the main ligand of FGFR2, are both overexpressed in 5-10% of breast tumors.
Nadine Reintjes, Yun Li, Alexandra Becker, Edyta Rohmann, Rita Schmutzler, Bernd Wollnik   +5 more
doaj   +1 more source

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Nature, 2022
Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer1.
D. Zingg, J. Bhin, Julia Yemelyanenko, S. Kas, F. Rolfs, C. Lutz, Jessica K. Lee, S. Klarenbeek, Ian M. Silverman, S. Annunziato, Chang S. Chan, S. Piersma, Timo Eijkman, Madelon Badoux, E. Gogola, Bjørn Siteur, Justin Sprengers, Bim de Klein, R. de Goeij-de Haas, G. Riedlinger, Hua Ke, R. Madison, Anne Paulien Drenth, Eline van der Burg, Eva Schut, L. Henneman, M. V. van Miltenburg, Natalie Proost, Huiling Zhen, E. Wientjens, Roebi de Bruijn, J. D. de Ruiter, U. Boon, Renske de Korte-Grimmerink, Bas van Gerwen, L. Féliz, G. Abou-Alfa, J. Ross, M. van de Ven, Sven Rottenberg, Edwin Cuppen, A. V. Chessex, Siraj M. Ali, Timothy C. Burn, Connie R Jimenez, Shridar Ganesan, L. Wessels, Jos Jonkers   +47 more
semanticscholar   +1 more source

Deletion of fibroblast growth factor receptor 2 from the peri-wolffian duct stroma leads to ureteric induction abnormalities and vesicoureteral reflux. [PDF]

PLoS ONE, 2013
Pax3cre-mediated deletion of fibroblast growth factor receptor 2 (Fgfr2) broadly in renal and urinary tract mesenchyme led to ureteric bud (UB) induction defects and vesicoureteral reflux (VUR), although the mechanisms were unclear. Here, we investigated
Kenneth A Walker, Sunder Sims-Lucas, Valeria E Di Giovanni, Caitlin Schaefer, Whitney M Sunseri, Tatiana Novitskaya, Mark P de Caestecker, Feng Chen, Carlton M Bates   +8 more
doaj   +1 more source

Tripod-shaped Syndactyly in Apert Syndrome with FGFR2 p.P253R Mutation

Indian Journal of Plastic Surgery, 2021
Apert syndrome is a rare acrocephalosyndactyly (craniosynostosis) syndrome characterized by craniofacial dysmorphism and syndactyly of the hands and feet. It is caused by FGFR2 mutations and inherited in an autosomal dominant manner.
Chandra Bhan Singh, Biswajit Mishra, Rashmi Patel, Ashok Kumar, Akhtar Ali   +4 more
doaj   +1 more source

Fetal microtia and FGFR2 polymorphism

Experimental and Therapeutic Medicine, 2019
Association of the single-nucleotide polymorphism (SNP) of rs3135718 site in fibroblast growth factor receptor 2 (FGFR2) gene with congenital microtia was investigated. A total of 193 patients with congenital microtia (observation group) and 150 normal and healthy fetuses (control group) treated in Maternity and Child Health Care of Zaozhuang from ...
Zhao, Ruilian, Du, Peixia, Sun, Hongmei, Yang, Li, Lin, Pingzhen   +4 more
openaire   +3 more sources

Clinical Features of Apert Syndrome in Infancy: A rare case in Indonesia

Scripta Score Scientific Medical Journal, 2021
Background: Apert syndrome is characterized by several malformations of cranial-facial and syndactyly. The incidence of Apert syndrome was reported at approximately 1 per 65,000 live births, globally.
Muhammad Pradhika Mapindra, Muhammad Pradhiki Mahindra   +1 more
doaj   +1 more source

Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression

International Journal of General Medicine, 2020
Attapol Titapun,1,2 Anchalee Techasen,2,3 Prakasit Sa-Ngiamwibool,2,4 Paiboon Sithithaworn,2,5 Vor Luvira,1,2 Tharatip Srisuk,1,2 Apiwat Jareanrat,1,2 Hasaya Dokduang,2,6 Watcharin Loilome,2,6 Bandit Thinkhamrop,2,7 Narong Khuntikeo1,2 1Department of ...
Titapun A, Techasen A, Sa-Ngiamwibool P, Sithithaworn P, Luvira V, Srisuk T, Jareanrat A, Dokduang H, Loilome W, Thinkhamrop B, Khuntikeo N   +10 more
doaj  

Harnessing the FGFR2/NF2/YAP signaling-dependent necroptosis to develop an FGFR2/IL-8 dual blockade therapeutic strategy

Nature Communications
The multifaceted roles and mechanisms of necroptosis in cancer cells remain incompletely understood. Here, we demonstrate that FGFR2 inhibition potently inhibits esophageal squamous cell carcinoma (ESCC) by inducing necroptosis in a RIP1/MLKL-dependent ...
Dongshao Chen, Zitong Zhao, Ruoxi Hong, Di Yang, Ying Gong, Qingnan Wu, Yan Wang, Yiren Cao, Jie Chen, Yidi Tai, Haoyu Liu, Jinting Li, Jiawen Fan, Weimin Zhang, Yongmei Song, Q. Zhan   +15 more
semanticscholar   +1 more source

Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib.

Cancer Discovery, 2020
Pemigatinib, a selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor, has demonstrated antitumor activity in FIGHT-202, a phase 2 study in patients with cholangiocarcinoma harboring FGFR2 fusions/rearrangements, and has gained regulatory ...
I. Silverman, A. Hollebecque, L. Friboulet, S. Owens, R. Newton, H. Zhen, L. Féliz, C. Zecchetto, D. Melisi, T. Burn   +9 more
semanticscholar   +1 more source